As filed with the U.S. Securities and Exchange Commission on March 31, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Calithera Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware | 27-2366329 | |
(State or other jurisdiction of Incorporation or organization) |
(I.R.S. Employer Identification No.) |
343 Oyster Point Blvd., Suite 200
South San Francisco, California 94080
(Address of principal executive offices) (Zip code)
Calithera Biosciences, Inc. 2014 Equity Incentive Plan
Calithera Biosciences, Inc. 2014 Employee Stock Purchase Plan
(Full title of the plans)
Susan M. Molineaux, Ph.D.
President and Chief Executive Officer
343 Oyster Point Blvd., Suite 200
South San Francisco, California 94080
(650) 870-1000
(Name and address of agent for service) (Telephone number, including area code, of agent for service)
Copies to:
John T. McKenna
David R. Ambler
Cooley LLP
3175 Hanover Street
Palo Alto, California 94304
(650) 843-5000
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
PART I
EXPLANATORY NOTE
Calithera Biosciences, Inc. (the Registrant) is filing this Registration Statement on Form S-8 for the purpose of registering an additional (a) 3,085,761 shares of its common stock, par value $0.0001 per share (the Common Stock), issuable to eligible persons under the 2014 Equity Incentive Plan, which Common Stock is in addition to the shares of Common Stock registered on the Registrants registration statements on Form S-8 filed on (i) October 2, 2014 (File No. 333-199126), (ii) May 11, 2015 (File No. 333-204056), (iii) March 15, 2016 (File No. 333-210193), (iv) March 16, 2017 (File No. 333-216740), (v) March 8, 2018 (File No. 333-223533), (vi) March 7, 2019 (File No. 333-230131), (vii) March 11, 2020 (File No. 333-237089) and (viii) March 16, 2021 (File No. 333-254351) (the Prior Forms S-8), and (b) 250,000 shares of Common Stock issuable to eligible persons under the 2014 Employee Stock Purchase Plan, which Common Stock is in addition to the shares of Common Stock registered on the Prior Forms S-8.
PART II
ITEM 3. | INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE |
Pursuant to General Instruction E to Form S-8, the contents of the Prior Forms S-8 are incorporated by reference herein.
The Registrant hereby incorporates by reference into this Registration Statement the following documents filed by it with the SEC:
(a) | the Registrants Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022; |
(b) | our Current Reports on Form 8-K filed with the SEC on January 5, 2022, January 28, 2022 and March 31, 2022 (with respect to Items 8.01 and 9.01 therein); and |
(c) | The description of the Common Stock contained in the Registrants Registration Statement on Form 8-A (File No. 001-36644) filed with the SEC on September 25, 2014 as updated by Exhibit 4.3 to our Annual Report on Form 10-K for the year ended December 31, 2019 and any amendments or reports filed for the purpose of updating such description. |
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
ITEM 8. | EXHIBITS |
Incorporated by Reference | ||||||||||
Exhibit |
Description |
Schedule Form |
File Number | Exhibit | Filing Date | |||||
4.1 | Amended and Restated Certificate of Incorporation of Calithera Biosciences, Inc. | 8-K | 001-36644 | 3.1 | October 7, 2014 | |||||
4.2 | Amended and Restated Bylaws of Calithera Biosciences, Inc. | 10-Q | 001-36644 | 3.2 | August 10, 2020 | |||||
4.3 | Form of Common Stock Certificate | S-1 | 333-198355 | 4.1 | September 25, 2014 | |||||
5.1* | Opinion of Cooley LLP. | |||||||||
23.1* | Consent of Independent Registered Public Accounting Firm. | |||||||||
23.2* | Consent of Cooley LLP (included in Exhibit 5.1). | |||||||||
24.1* | Power of Attorney (see signature page hereto). | |||||||||
99.1 | Calithera Biosciences, Inc. 2014 Equity Incentive Plan., as amended | 8-K | 001-36644 | 99.1 | January 26, 2021 | |||||
99.4 | 2014 Employee Stock Purchase Plan. | S-1 | 333-198355 | 10.6 | September 25, 2014 | |||||
107* | Filing Fee Table |
* | Filed herewith |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of South San Francisco, State of California, on March 31, 2022.
CALITHERA BIOSCIENCES, INC. | ||
By: | /s/ Susan M. Molineaux | |
Susan M. Molineaux, Ph.D. | ||
President and Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Susan M. Molineaux, Ph.D. and Stephanie Wong, and each or any one of them, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitutes or substitute, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ Susan M. Molineaux Susan M. Molineaux, Ph.D. |
President, Chief Executive Officer and Director (Principal Executive Officer) |
March 31, 2022 | ||
/s/ Stephanie Wong Stephanie Wong |
Chief Financial Officer and Secretary (Principal Financial and Accounting Officer) |
March 31, 2022 | ||
/s/ Sunil Agarwal Sunil Agarwal, M.D. |
Director | March 31, 2022 | ||
/s/ Jonathan G. Drachman Jonathan G. Drachman, M.D. |
Director | March 31, 2022 | ||
/s/ Scott Garland Scott Garland |
Director | March 31, 2022 | ||
/s/ Suzy Jones Suzy Jones |
Director | March 31, 2022 | ||
/s/ Keith Orford Keith Orford, M.D., Ph.D. |
Director | March 31, 2022 | ||
/s/ Deepa R. Pakianathan Deepa R. Pakianathan, Ph.D. |
Director | March 31, 2022 | ||
/s/ Blake Wise Blake Wise |
Director | March 31, 2022 | ||
/s/ H. Ward Wolff H. Ward Wolff |
Director | March 31, 2022 |
Exhibit 5.1
David Ambler
+1 650 843 5899
dambler@cooley.com
March 31, 2022
Calithera Biosciences, Inc.
343 Oyster Point Blvd. Suite 200
South San Francisco, California 94080
Ladies and Gentlemen:
We have acted as counsel to Calithera Biosciences, Inc., a Delaware corporation (the Company), in connection with the filing of a registration statement on Form S-8 (the Registration Statement) with the Securities and Exchange Commission covering the offering of up to 3,335,761 shares (the Shares) of the Companys Common Stock, par value $0.0001 per share (Common Stock), consisting of (a) 3,085,761 shares of Common Stock issuable pursuant to the Companys 2014 Equity Incentive Plan (the 2014 Plan) and (b) 250,000 shares of Common Stock issuable pursuant to the Companys 2014 Employee Stock Purchase Plan (together with the 2014 Plan, the Plans).
In connection with this opinion, we have examined and relied upon (a) the Registration Statement and related prospectuses, (b) the Plans, (c) the Companys Amended and Restated Certificate of Incorporation, including its Certificate of Designations of Preferences, Rights and Limitations of Series A Preferred Stock, and Amended and Restated Bylaws, each as currently in effect and (d) originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, and the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.
Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.
On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectuses, will be validly issued, fully paid, and nonassessable (except as to shares issued pursuant to deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).
Cooley LLP 3175 Hanover Street Palo Alto, CA 94304-1130
t: (650) 843-5000 f: (650) 849-7400 cooley.com
Calithera Biosciences, Inc.
March 31, 2022
Page Two
We consent to the filing of this opinion as an exhibit to the Registration Statement.
Sincerely,
Cooley LLP
By: | /s/ David Ambler | |
David Ambler |
Cooley LLP 3175 Hanover Street Palo Alto, CA 94304-1130
t: (650) 843-5000 f: (650) 849-7400 cooley.com
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Calithera Biosciences, Inc. 2014 Equity Incentive Plan and the Calithera Biosciences, Inc. 2014 Employee Stock Purchase Plan of our report dated March 31, 2022, with respect to the consolidated financial statements of Calithera Biosciences, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2021, filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Redwood City, CA
March 31, 2022
Exhibit 107
CALCULATION OF FILING FEE TABLES
Form S-8
Calithera Biosciences, Inc.
Table 1: Newly Registered Securities
Security Type |
Security Class Title |
Fee Calculation Rule |
Amount to be Registered(1) |
Proposed Maximum Offering Price Per Share |
Proposed Maximum Aggregate Offering Price |
Fee Rate | Amount of Registration Fee |
|||||||||||||||||||
Equity |
2014 Equity Incentive Plan (Common stock, $0.0001 par value per share) | Other | 3,085,761 | (2) | $ | 0.54 | (4) | $ | 1,666,310.94 | .0000927 | $ | 154.47 | ||||||||||||||
Equity |
2014 Employee Stock Purchase Plan (Common stock, $0.0001 par value per share) | Other | 250,000 | (3) | $ | 0.54 | (5) | $ | 135,000.00 | .0000927 | $ | 12.52 | ||||||||||||||
|
|
|
|
|||||||||||||||||||||||
Total Offering Amounts |
|
$ | 1,801,310.92 | $ | 166.99 | |||||||||||||||||||||
|
|
|
|
|||||||||||||||||||||||
Total Fee Offsets |
|
N/A | ||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||
Net Fee Due |
|
$ | 166.99 | |||||||||||||||||||||||
|
|
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the Securities Act), this Registration Statement shall also cover any additional shares of common stock that become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without receipt of consideration which results in an increase in the number of Calithera Biosciences, Inc.s (the Registrant) outstanding shares of common stock, par value $0.0001 per share (the Common Stock). |
(2) | Represents additional shares of the Registrants Common Stock reserved for future grant under the Calithera Biosciences, Inc. 2014 Equity Incentive Plan (the 2014 Plan) as a result of the automatic increase in shares reserved thereunder on January 1, 2022 pursuant to the terms of the 2014 Plan. The 2014 Plan provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the 2014 Plan on January 1, 2022 and ending on (and including) January 1, 2024 in an amount equal to 4% of the total number of shares of the Registrants capital stock outstanding on December 31st of the preceding calendar year, except that, before the date of any such increase, the Registrants board of directors may determine that the increase for such year will be a lesser number of shares. |
(3) | Represents additional shares of the Registrants Common Stock reserved for issuance under the Calithera Biosciences, Inc. 2014 Employee Stock Purchase Plan (the ESPP) as a result of the automatic increase in shares reserved thereunder on January 1, 2022 pursuant to the terms of the ESPP. The ESPP provides that an additional number of shares will automatically be added annually to the shares authorized for issuance under the ESPP on January 1, 2022 and ending on (and including) January 1, 2024. The number of shares added each year will be equal to the lesser of: (a) 1% of the total number of shares of the Registrants capital stock outstanding on December 31 of the preceding calendar year and (b) 250,000 shares of Common Stock, except that, before the date of any such increase, the Registrants board of directors may determine that there will be no such increase or that the increase for such year will be less than the amount set forth in clauses (a) and (b). |
(4) | Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $0.54 per share, which is the average of the high and low prices of the Common Stock as reported on The Nasdaq Global Select Market on March 25, 2022, rounded up to the nearest cent. |
(5) | Estimated pursuant to Rule 457(c) and Rule 457(h) solely for the purpose of calculating the registration fee on the basis of $0.54 per share, which is 85% of the average of the high and low prices of the Common Stock as reported on The Nasdaq Global Select Market on March 25, 2022, rounded up to the nearest cent. |